TITLE

Lentiviral vectors ready for prime-time

AUTHOR(S)
Kohn, Donald B.
PUB. DATE
January 2007
SOURCE
Nature Biotechnology;Jan2007, Vol. 25 Issue 1, p65
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on the paper presented on a clinical trial, in which an anti-HIV-1 gene is transferred and expressed using a lentiviral vector. The author suggests that the trial demonstrated safe gene delivery to patients' T-cells and that lentiviral vectors can be effectively used in treating various disorders. The author gives details related to lentiviral vectors and concludes that the vectors play a vital role in advancing gene therapy applications in different conditions.
ACCESSION #
23625861

 

Related Articles

  • Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Humeau, Laurent M.; Binder, Gwendolyn K.; Lu, Xiaobin; Slepushkin, Vladimir; Merling, Randall; Echeagaray, Patricia; Pereira, Mario; Slepushkina, Tatiana; Barnett, Scott; Dropulic, Lesia K.; Carroll, Richard; Levine, Bruce L.; June, Carl H.; Dropulic, Boro // Molecular Therapy;Jun2004, Vol. 9 Issue 6, p902 

    We present preclinical studies that demonstrate in vitro the feasibility and efficacy of lentivirus-based vector antisense gene therapy for control of HIV replication in primary T lymphocytes isolated from HIV-infected patients discordant for clinical status. VRX496 is a VSV-G-pseudotyped...

  • Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy? Collins, Sara A.; Guinn, Barbara-ann; Harrison, Patrick T.; Scallan, Martina F.; O'Sullivan, Gerald C.; Tangney, Mark // Current Gene Therapy;Apr2008, Vol. 8 Issue 2, p66 

    Gene therapy involves the transfer of genetic information to a target cell to facilitate the production of therapeutic proteins and is now a realistic prospect as a cancer treatment. Gene transfer may be achieved through the use of both viral and non-viral delivery methods and the role of this...

  • Gene therapy in sport. Trent, R. J.; Alexander, I. E. // British Journal of Sports Medicine;Jan2006, Vol. 40 Issue 1, p4 

    The article presents information on the use of gene therapy in sports. It was first envisaged as an approach to treat genetic disorders. Gene therapy covers many clinical problems including genetic diseases, cancer, infections such as HIV and degenerative diseases. Although used extensively, the...

  • Gene Therapy for Parkinson's and Alzheimer's Diseases: from the Bench to Clinical Trials. Nobre, Rui Jorge; De Almeida, Luís Pereira // Current Pharmaceutical Design;10/21/2011, Vol. 17 Issue 31, p3434 

    Alzheimer's and Parkinson's diseases represent the most prevalent neurodegenerative disorders worldwide. Current pharmacological or surgical treatments provide symptomatic benefits, particularly in the early stages, but none can delay or stop the progression of these diseases. There is an urgent...

  • Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy. Breyer, Benjamin; Wei Jiang; Hongwei Cheng; Lan Zhou; Ronjon Paul; Tao Feng; Tong-Chuan He // Current Gene Therapy;Jul2001, Vol. 1 Issue 2, p149 

    Human gene therapy promises to change the practice of medicine by treating the causes of disease rather than the symptoms. Since the first clinical trial made its debut ten years ago, there are over 400 approved protocols in the United States alone, most of which have failed to show convincing...

  • Primer on Medical Genomics Part X: Gene Therapy. Russell, Stephen J.; Peng, Kah-Whye // Mayo Clinic Proceedings;Nov2003, Vol. 78 Issue 11, p1370 

    Gene therapy is defined as any therapeutic procedure in which genes are intentionally introduced into human somatic cells. Both preclinical and clinical gene therapy research have been progressing rapidly during the past 15 years; gene therapy is now a highly promising new modality for the...

  • Efficient Marking of Murine Long-Term Repopulating Stem Cells Targeting Unseparated Marrow Cells at Low Lentiviral Vector Particle Concentration. Kurre, Peter; Anandakumar, Ponni; Harkey, Michael A.; Thomasson, Bobbie; Kiem, Hans-Peter // Molecular Therapy;Jun2004, Vol. 9 Issue 6, p914 

    HIV-1-derived lentivirus vectors offer unique biological properties for gene delivery to hematopoietic stem cells and, when used at high multiplicities of infection (m.o.i.), permit efficient gene transfer after minimal target cell stimulation. However, such a strategy has been shown to promote...

  • Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Schroers, R.; Davis, C.M.; Wagner, H.-J.; Chen, S.-Y. // Gene Therapy;7/1/2002, Vol. 9 Issue 13, p889 

    Intrakines, modified intracellular chemokines, offer a novel strategy to prevent cellular entry of HIV-1 by blocking the surface expression of HIV-1 co-receptors. To investigate potential clinical applications of the RANTES-intrakine, we explored the use of HIV-1-based lentiviral vectors for...

  • Gene Therapy of HIV-1 Infection Using Lentiviral Vectors Expressing Anti-HIV-1 Genes. Mautino, Mario R.; Morgan, Richard A. // AIDS Patient Care & STDs;Jan2002, Vol. 16 Issue 1, p11 

    The use of vectors based on primate lentiviruses for gene therapy of human immunodeficiency virus type 1 (HIV-1) infection has many potential advantages over the previous murine retroviral vectors used for delivery of genes that inhibit replication of HIV-1. First, lentiviral vectors have the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics